Skip to main content

Table 5 Comparison of different adjuvant chemoradiation studies

From: Postoperative chemoradiation for resected gastric cancer - is the Macdonald Regimen Tolerable? a retrospective multi-institutional study

First author

(country, year)

Type of study

No. of patients

Type of chemotherapy

T3-4

N+

Any Gr ≥ 3 tox.

Gr > 3 Hem. tox.

Gr > 3 Non- hem. tox.

Toxic deaths

Relapse rate

Median survival (months)

MacDonald [4]

(USA, 2001)

Phase 3

556

5FU/LV1

66%

85%

41%

54%

63%

1%

43%

36

Park [18]

(South-Korea,2003)

Phase 2

290

5FU/LV

NA

90%

NA

30%

38%

0%

39%

NA

Hughes [14]

(Australia, 2004)

Retrosp.

452

5FU/LV

85%

81%

42%

18%

20%

0%

68%

22.8

Kollmannsberger [20]

(Germany, 2005)

Phase 2

86

DDP/5FU

PAC/DDP/5FU/LV4

NA

NA

NA

81% 89%

56% 56%

0%

0%

19%

33%

NA

NA

Kim [9]

(South Korea, 2005)

Retrosp.

990

5FU/LV

48%

93%

NA

30%

15%

1%

42%

95

Kassam [15]

(Canada, 2006)

Retrosp.

822

5FU/LV3

DDP/5FU

53%

82%

56%

33%

34%

0%

32%

NR

Lee [19]

(South-Korea, 2006)

Phase 2

31

DDP/5FU

NA

100%

NA

66%

12%

0%

13%

NA

Oechsle [8]

(Germany,2007)

Phase 2

157

DDP/PAC/5FU/LV

NA

NA

NA

100%

58%

0.6%5

51%

NA

   

DDP/5FU/LV

   

93%

59%

 

52%

NA

   

CPT11/5FU/LV

   

80%

73%

 

100%

NA

   

DOC/DDP/5FU

   

100%

30%

 

30%

NA

Tsang13]

(Hong Kong, 2008)

Retrosp.

632

5FU/LV

52%

86%

30%

24%

14%

1.5%

52%

NR

Hofheinz [16]

Germany, 2008)

Extend. phase I

322

CAPE/OXALI

44%

97%

NA

21%

42%

0%

47%

NA

Di Costanzo [7]

(Italy, 2008)

Phase 3

258

DDP/EPI/5FU/LV1

54%

84%

NR

27%

75%

0.8%

48%

57

Leong [22]

(Australia, 2009)

Phase 2

54

EPI/DDP/5FU

57%

98%

NA

28%

66%

0%

37%

NR

Aftimos [21]

(Lebanon, 2010)

Retrosp.

24

5FU/LV

DDP/5FU

75%

71%

NA

20%

36%

0%

22%

75

Chang [17]

(Hong Kong, 2011)

Retrosp.

1202

5FU/LV

45%

93%

66%

61%

15%

0%

41%

64

Current

(Israel, 2011)

Retrosp.

166

5FU/LV

77%

85%

46%

32%

25%

1.8%

30%

NR

  1. Tox. = toxicity, Hem. = hematological, Extend. = extended, Retrosp. = retrospective, DDP = cisplatin, PAC = paclitaxel, EPI = epirubicin, CAP = capecitabine, OX = oxaliplatin, DOC = docetaxel, 5FU = 5 fluorouracil, LV = Leucovorin. NR = not reached, NA = not available.
  2. 1The regimen used in the treatment arm. The control arm included surgery alone.
  3. 2These studies included also patients undergoing R1 resection; results of outcome represent patients undergoing R0 resection,
  4. whenever reported separately.
  5. 3Combined analysis of more than one regimen.
  6. 4Combined report of consecutive phase II cohorts.
  7. 5Joint figure for all cohorts combined